Archive · 15 Dec 2025
Ozempic Launched in India for Diabetes
Ozempic, a diabetes drug, has been launched in India by Novo Nordisk.
It helps control blood sugar levels and supports weight loss.
The company emphasizes that it's meant for diabetes treatment, not just weight loss.
They warn against self-medication and misuse, stressing the importance of medical supervision.
Ozempic has been priced affordably in India, but the company also highlights the need for lifestyle changes alongside medication.
They reject the idea of it being a 'miracle drug' and focus on responsible use to manage diabetes and obesity.
Medical professionals caution that the drug should be used under strict supervision due to potential side effects and the unique metabolic characteristics of Indians.
Ozempic (semaglutide) has been launched in India by Novo Nordisk for type 2 diabetes treatment.
The drug offers a more holistic option for diabetes care, reducing HbA1c levels and supporting weight loss.
Novo Nordisk emphasizes that Ozempic is not a 'miracle drug' and should be used responsibly under medical supervision.
The company has priced Ozempic affordably in India, aiming to balance commercial sustainability with patient access.
Medical professionals caution against misuse and emphasize the need for strict medical supervision due to potential side effects and the unique metabolic characteristics of Indians.
- Who
- Novo Nordisk India, led by Managing Director Vikrant Shrotriya
- What
- Launch of Ozempic (semaglutide) for type 2 diabetes treatment in India
- When
- December 14, 2025
- Where
- India
- Why
- To provide a more holistic option for diabetes care and address the significant diabetes burden in India
Medical Professionals
General Public
Usage and Dosage
Medical Professionals
Medical professionals emphasize that Ozempic should be used under strict medical supervision and according to prescribed dosages. They caution against microdosing and highlight the need for a case-by-case approach to tapering doses.
General Public
Some individuals may seek Ozempic for cosmetic reasons or without proper medical guidance, potentially leading to misuse.
Long-term Use
Medical Professionals
Doctors suggest that Ozempic should be used indefinitely for chronic conditions like diabetes and obesity, similar to other long-term medications.
General Public
Patients may be concerned about continuing the drug indefinitely and may seek to taper down the dosage without medical advice.
- Drug Name
- Ozempic (semaglutide)
- Manufacturer
- Novo Nordisk
- Primary Use
- Type 2 Diabetes
- Price in India
- Rs 8,800 to Rs 11,175 per month
- Key Benefit
- Reduces HbA1c levels and supports weight loss
- Target Population
- Over 100 million adults with type 2 diabetes in India
- Safety
- Extensively evaluated by global and Indian regulators
- Company Stance
- Advocates against self-medication and misuse
- Common Side Effects
- Nausea, vomiting, diarrhea, constipation
- Rare Side Effects
- Potential impacts on pancreas or other organs under scrutiny
